A major healthcare scandal has come to light in South Korea as a former hospital director blows the whistle on a widespread insurance fraud scheme. Nearby cancer care facilities are allegedly inflating non-insured treatment fees and offering illegal cash refunds to patients, all while billing the maximum amount to private real-loss insurance policies.
The Anatomy of the Cash-Back Scheme
According to Director A, the former head of a cancer care hospital in Hwasun, Jeollanam-do, the fraudulent system relies on manipulating non-insured medical fees.
-
The Inflated Billing: A hospital artificially inflates the cost of a procedure. For example, a low-frequency hyperthermia cancer treatment normally priced at 300,000 won is billed at 500,000 won.
-
The Kickback: Once the patient’s real-loss insurance policy covers the full 500,000 won, the hospital secretly refunds 200,000 won in cash back to the patient.
The Illusion of Free Money: While patients believe they are profiting from these cash returns, Director A warns that the practice backfires dramatically. The inflated claims rapidly deplete a patient’s annual real-loss insurance coverage limit, cutting a full year’s worth of vital cancer treatments down to just five or six months.
Collateral Damage: Broken Clinics and Rising Premiums
The consequences of this systemic fraud extend far beyond individual policy limits, damaging the broader healthcare infrastructure:
-
Distorted Competition: Honest medical facilities are being driven out of business. Director A revealed that his own clinic was forced to close after losing 200 million won monthly. Patients systematically abandoned his hospital for neighboring facilities that offered higher cash-back rates.
-
Skyrocketing Premiums: Massively inflated payouts have triggered a spike in insurance costs. Premiums for South Korea’s first- through fourth-generation real-loss insurance policies rose by an average of 7.8% this year alone, threatening to price vulnerable populations out of coverage.
-
Subpar Care: Director A emphasized that when hospitals prioritize financial kickbacks over medicine, the quality of oncology care inevitably plummets, leaving cancer patients as the ultimate victims.
Systemic Leakage and the Regulatory Response
Though Director A first filed complaints with local health centers and the Jeollanam-do Office in July 2023, the issue was largely ignored for three years. Authorities claimed initial investigations turned up no evidence, a conclusion Director A fiercely disputes, citing a systemic “lack of will” to investigate a crime where patients appear uninjured on the surface.
However, the Ministry of Health and Welfare has finally launched a massive crackdown following staggering data updates from the Financial Supervisory Service (FSS) and industry reports:
| Metric | Current Status / Impact |
| Undetected Fraud Estimate | The Financial Services Commission (FSC) estimates total fraud could reach 9 trillion won. |
| Detected Fraud (2025) | Reached a record 1.16 trillion won, up from 1.12 trillion won in 2023. |
| Real-Loss Share of Fraud | Long-term non-life insurance accounts for 44.7% of all detected fraud cases. |
| Cancer Immune Injections | Claims for these unproven treatments soared to 51.6 billion won in Q1 2026 (a 21% YoY increase). |
This surge in fraudulent activity is compounding an already stressed system. According to a WTW report, South Korea’s projected gross medical cost trend for 2026 is a staggering 13.5%, driven heavily by fraud, waste, abuse, and advanced pharmaceutical costs.
Government officials warn that if left unchecked, this widespread real-loss insurance leakage will inevitably deplete the national health insurance fund, jeopardizing healthcare access for the entire country.
